Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Please can you tell us in your own words how you’ve seen the Mexican pharmaceutical market change over the past five years? Mexico is one of the top ten markets…
You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time?…
Please can you give us a brief rundown of Pierre Fabre’s activities in Mexico since they opened an affiliate here, specifically the company’s milestones and achievements along the way? Pierre…
Since we last spoke to you in 2008, Mexico has undergone a lot of regulatory changes, and we witnessed the rise of Seguro Popular, and the rise of COFEPRIS for…
Grünenthal first started operations in Mexico back in 1998, we then interviewed Mr. Klaus Kuchen in 2005, but we want to know what’s happened since. Please can you give us…
There are about 250 employees and you have regional presence in Latin America. In your view as CEO, can you tell our readers about the biggest growth drivers and challenges…
You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here 11 years ago? The…
Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way? Shire started operations in…
Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When Octapharma first came to…
From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years?…
See our Cookie Privacy Policy Here
